Elsewhere on Ulster
This project is funded by:
The global rise in obesity and Type 2 Diabetes is not just a metabolic crisis; it is driving a hidden epidemic of subfertility in both men and women. This exciting PhD project explores the "gut-gonadal axis," investigating how systemic metabolic dysfunction impairs reproductive health and, crucially, how we can reverse it.
You will investigate the next frontier of metabolic pharmacology: advanced proglucagon-derived and rationally engineered hybrid peptides (e.g., dual incretin agonists). While these cutting-edge therapeutics have revolutionized diabetes and weight management, their potential to rescue fertility remains a massive, untapped clinical frontier.
Joining the dynamic Diabetes Research Group at Ulster University, you will develop highly sought-after skills in molecular endocrinology, peptide biology, and complex in vivo metabolic phenotyping. Using high-energy dietary murine models, you will rigorously assess how novel peptide candidates restore glycemic control, repair steroidogenic machinery, and regenerate reproductive tissue architecture.
Uniquely, this project is highly translational. Designed with a strong commercial and clinical focus, you will bridge the gap between academic discovery and patient care. Working alongside potential clinical fertility partners, you will cross-validate your pre-clinical biomarker discoveries with human clinical pathways, gaining invaluable exposure to the Life and Health Sciences industry and commercial regulatory landscape.
If you are a motivated graduate passionate about metabolic disease, reproductive endocrinology, and drug discovery, this project offers an exceptional multidisciplinary training environment. You will graduate as a highly employable scientist uniquely equipped to navigate both academic research and commercial biotechnology.
Please note: Research Proposal - 5 pages in total
The proposal must include:
Please also note that the use of AI in generating the research proposal is prohibited.
Important Information: Applications for more than one PhD studentship are welcome, however if you apply for more than one PhD project within Biomedical Sciences/Pharmacy and Pharmaceutical Sciences, your first application on the system will be deemed your first-choice preference and further applications will be ordered based on the sequential time of submission.
If you are successfully shortlisted, you will be interviewed only on your first-choice application and ranked accordingly. Those ranked highest will be offered a PhD studentship.
In the situation where you are ranked highly and your first-choice project is already allocated to someone who was ranked higher than you, you may be offered your 2nd or 3rd choice project depending on the availability of this project.
Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.
We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.
In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.
If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.
The University is an equal opportunities employer and welcomes applicants from all sections of the community, particularly from those with disabilities.
Appointment will be made on merit.
This project is funded by:
PhD scholarships are available for this project to all applicants worldwide, regardless of residency or domicile, and will cover:
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year, or part-time equivalent, funded from any source, including self-financing students, are NOT eligible to apply for an award.
Students in full-time employment are not eligible for an award.
Part-time PhD scholarships may be available at a 0.5 pro rata rate of the full-time scholarship, which would require a six-year registration period.
Due consideration should be given to financing your studies.
The University will award a successful candidate one of the following scholarships for the project, depending on the funding available at the time an admissions offer is made:
Please note that the Terms and Conditions for scholarships are subject to change for 2027/28.
Khan, D., Sridhar, A., Flatt, P.R. and Moffett, R.C., 2023. Disturbed ovarian morphology, oestrous cycling and fertility of high fat fed rats are linked to alterations of incretin receptor expression. Reproductive biology, 23(3), p.100784.
Broughton, D. E., & Moley, K. H. (2017). Obesity and female infertility: potential mediators of obesity's impact. Fertility and Sterility, 107(4), 840 847.
Sridhar, A., Khan, D. and Moffett, R.C., 2023. The impact of diabetes and obesity on fertility and the potential role of gut hormones as treatment. Diabetic Medicine, 40(12), p.e15230.
Khan, D., Ojo, O. O., Woodward, O. R., Lewis, J. E., Sridhar, A., Gribble, F. M., ... & Moffett, R. C. (2022). Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice. Biomolecules, 12(12), 1736.
Jensterle, M. and Janez, A., 2026. Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map: M. Jensterle, A. Janez. Drugs, pp.1-20.
Submission deadline
Friday 8 January 2027
04:00PM
Interview Date
8th -16th February 2027
Preferred student start date
13th September 2027
Telephone
Contact by phone
Email
Contact by email